<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949737</url>
  </required_header>
  <id_info>
    <org_study_id>20_RIPH2_22</org_study_id>
    <secondary_id>2020-A02412-37</secondary_id>
    <nct_id>NCT04949737</nct_id>
  </id_info>
  <brief_title>Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies</brief_title>
  <acronym>HÃ©lico-MQ</acronym>
  <official_title>Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies: Helico-MQ Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Center of Martinique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Center of Martinique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estimating the prevalence of Helicobacter Pylori infection in newly diagnosed stomach cancers&#xD;
      in the West-Indies will help to understand the epidemiology of this cancer, which is&#xD;
      over-incident in the West Indies compared to France. In addition, the constitution of a&#xD;
      biobank (tumor tissues, healthy tissues and serum) will allow to set up in a second time&#xD;
      etiological studies to identify other risk factors in particular in connection with the&#xD;
      exposure to environmental pollutants to adapt the prevention measures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Antilles-Guyana, gastric cancer affects approximately 80 men and women each year in&#xD;
      Guadeloupe and Martinique, and 20 in French Guiana. It is more frequent than in France and&#xD;
      represents 4.5% of cancers in men in Martinique, 5.3% in Guadeloupe and 5.7% in French&#xD;
      Guyana. It is the 3rd most common cancer site in men in Guadeloupe and Martinique, and the&#xD;
      4th in French Guiana. In women, it is the 3rd most frequent cancer in Martinique and the 4th&#xD;
      in Guadeloupe, whereas it is less frequent in French Guiana.&#xD;
&#xD;
      Studies are needed to estimate this prevalence in the general population and in cancer&#xD;
      patients. The prevalence of Helicobacter pylori infection is not well known in the general&#xD;
      population in the Caribbean and when gastric cancer is diagnosed, the bacterium is rarely&#xD;
      tested.&#xD;
&#xD;
      Dietary habits in our regions are characterized by a high consumption of salt (salted), meat&#xD;
      and smoked fish. These dietary habits, common to some Southeast Asian countries, could partly&#xD;
      explain the high incidence of stomach cancer observed. But environmental risk factors could&#xD;
      also be involved.&#xD;
&#xD;
      Patients referred to gastroenterology with a suspected endoscopic diagnosis of gastric cancer&#xD;
      will be offered to participate in the study after the fibroscopy has been performed and their&#xD;
      consent will be obtained for the use of diagnostic specimen remains for research purposes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of the prevalence of Helicobacter pylori</measure>
    <time_frame>At baseline</time_frame>
    <description>Helicobacter Pylori has detected by immunohistochemistry in the stomach of patients with gastric cancer.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Gastric Neoplasms</condition>
  <condition>Helicobacter Pylori</condition>
  <arm_group>
    <arm_group_label>Helicobacter Pylori detection</arm_group_label>
    <description>Systematic biopsies of the tumor and the gastric cavity will be performed during the initial fibroscopy in accordance with the recommendations of the French Society of Digestive Endoscopy (SFED).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Helicobacter Pylori detection</intervention_name>
    <description>Biopsies will be sent to the referral anatomopathology laboratory. The search for Helicobacter pylori will be performed by immunohistochemistry. An additional blood sample for serological testing will be taken during the initial workup.&#xD;
Additional data will be collected through a questionnaire.</description>
    <arm_group_label>Helicobacter Pylori detection</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples retained for extraction of DNA from whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible patients (with a suspected endoscopic diagnosis of gastric cancer) will be&#xD;
        selected either at the Martinique University Hospital or at the Sainte-Marie clinic during&#xD;
        consultations or hospitalizations.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient over 18 years of age, residing for at least 6 months in Martinique, with a&#xD;
             primary diagnosis of gastric cancer&#xD;
&#xD;
          2. Patient having read the information note and having signed the consent to participate&#xD;
             in the study&#xD;
&#xD;
          3. Patient with social security coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refusal to participate&#xD;
&#xD;
          2. Patient who could not answer the questionnaires&#xD;
&#xD;
          3. Patient not affiliated to a social security system&#xD;
&#xD;
          4. Patient not fluent in French&#xD;
&#xD;
          5. Patient under legal protection (legal protection, guardianship, curators, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clarisse JOACHIM-CONTARET</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Martinique</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clarisse JOACHIM-CONTARET</last_name>
    <phone>+596596559674</phone>
    <email>clarisse.joachim@chu-martinique.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mickaelle ROSE</last_name>
    <phone>+596596592623</phone>
    <email>mickaelle.rose@chu-martinique.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Martinique</name>
      <address>
        <city>Fort-de-France</city>
        <zip>97261</zip>
        <country>Martinique</country>
      </address>
    </facility>
    <contact>
      <last_name>Mickaelle ROSE</last_name>
      <phone>+596596592623</phone>
      <email>mickaelle.rose@chu-martinique.fr</email>
    </contact>
    <investigator>
      <last_name>Julien FALLER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry BORTUZZO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguelle MAROUS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Martinique</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter Pylori</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Prevalence</keyword>
  <keyword>French West-Indies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

